TSHA NASDAQ
Taysha Gene Therapies, Inc.
1W: -0.9%
1M: -17.9%
3M: -27.4%
YTD: -11.8%
1Y: +45.6%
3Y: +55.9%
5Y: -76.9%
$4.63
-0.11 (-2.32%)
Weekly Expected Move ±5.9%
$4
$4
$5
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2022-10-25
Earliest Filing
2025-11-04
Latest Filing
partner: 7
Counterparties (Filed by TSHA)
7 relationshipsCompanies named in TSHA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Goldman Sachs & Co. LLC | GSCE | partner | Sales agent for the Company's common stock offering | 2025-11-04 | View |
| Leerink Partners LLC | — | partner | Sales agent whose agreement was amended and terminated | 2025-11-04 | View |
| Audentes Therapeutics, Inc. | — | partner | Licensee with option to exercise under Option Agreement | 2025-05-29 | View |
| Audentes Therapeutics, Inc. | — | partner | Entered into Option Agreement, Securities Purchase Agreement, and Registration Rights Agreement for TSHA-120 and TSHA-10 | 2022-10-31 | View |
| Astellas | — | partner | Operating name (d/b/a) of Audentes Therapeutics, Inc. in the agreements. | 2022-10-31 | View |
| Audentes Therapeutics, Inc. | — | partner | Entered into an Option Agreement and Securities Purchase Agreement for gene therapy product rights and equity investment | 2022-10-25 | View |
| Astellas | — | partner | Operating name of Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) involved in the Option and Securities Purcha | 2022-10-25 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-06-25 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-06-22 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-02 | Shareholder Vote | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2025-11-04 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Financial S | Agreement | View |
| 2025-10-16 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-02 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-03 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-05-29 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-05-29 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-28 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-15 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-26 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2024-06-26 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR